



defytime™

Business Plan

Reverse Aging Through Telomere Lengthening

Contents

Business Summary	3
Company	4
Our Research Team	5, 6
Telomeres	7
Telomerase	8
What is Aging?	9
Causes & Treatment of Aging	10
- Telomerase InductionAnti Aging Therapeutic	11
- Telomerase Induction Nano Bubbled Solution	12
TAM CO314818	13
TAM Clinical Studies	14
Defytime Bill Andrews Aging Care Capsules	15
Defytime Aging Care Cream	16
Defytime Eye Serum	17
Defytime Deep Skin Express	18
Defytime Aqua Oil Drops	19
Defytime TAM Spray	20
Defytime Facial Mask	21
Brand Marketing Strategy	22
SWOT Analysis	23
Road Map Expectation	24
Requested Investment	25
Cosmeceutical Estimated Sales	24,25,26,27,28,29,30
Non-medicated Item Estimated Sales	31, 32
Cash Flow Analysis Assumptions	33
About Nano-bubble Clinic	34
Nano-bubble Clinic Estimated Sales	35
Defytime Estimated Sales	36
Defytime Limited Valuation	37, 38
Company & Brand Structure	39
Proposed Summary Terms	40
Company Structure	41

Business Summary

We have developed a genuine anti aging solution called TAM

We now have a range of anti aging products: aging care capsule, oral spray and dermal products

Our objectives are:

- To create products with TAM (Telomerase Activating Molecule) as an active ingredient
- To launch non-medicated and skin care products to introduce to the cosmetic market
- VVIP anti aging tour business
- To create telomere lengthening oral & dermal products for anti aging, aging care, and sell Defytime products through high end sales channels
- To develop further premium anti aging products with TAM and non-medicated products
- South Pacific & NZ Clinic could provide genuine anti aging services to VVIP anti aging tour groups

Company

Defytime Ltd is headquartered in Auckland New Zealand, with labs research and development in Reno, Nevada USA

Our goal is to reverse the human aging process and cure diseases linked to aging by activating telomerase and thus extending telomeres, leading the cells to return to a state of youthful gene expression and function

This cutting-edge research is led by **Dr. Bill Andrews.**

Dr Andrews has worked in the biotech industry for over 35 years, focusing the last 20 years on finding ways to extend human lifespan through the intervention of telomere shortening in human cells



Our Research Team

Dr Bill Andrews

Chief Scientist of Research & Discovery



Dr Andrews earned his Ph D in Molecular and Population Genetics at the University of Georgia in 1981. He was a Senior Scientist at Armos Corp and Codon Corp, Director of Molecular Biology at Codon and at Geron Corp, and Director of Technology Development at EOS Biosciences. While Director of Molecular Biology at Geron Corp from 1992 to 1997, Dr Andrews was one of the principal discoverers of both the RNA and protein components of human telomerase and was awarded 2nd place as "National Inventor of the Year" in 1997 for this work.

He is named inventor on 45 US issued telomerase patents. Dr Andrews is highly respected and widely known for his expertise and passion for curing aging and TEDS. He has been a featured expert in many documentaries and is a frequent guest speaker at prestigious events. Dr Andrews is also an ultra marathon runner whose ultimate goal is to run a 7-minute mile at the age of 130.

Laura A Briggs, Ph D

Top Scientist of Research & Discovery



Laura Briggs received her B S degree in Nutrition in 1993 and her Ph D in Environmental Science and Health in 2000 from the University of Nevada, Reno. After a one year post-doctoral position at UNR, she joined Sierra Sciences, known as Andrews Inc in 2001. In addition to coordinating research and development at Sierra Sciences, Dr Briggs is also serving as the Biology Lab Coordinator for Truckee Meadows Community College (TMCC) and has collaborated on research projects at the VA Medical Center in Reno, Nevada.

Lancer Brown, M S

Program Director of Screening



Lancer Brown received his B S and M S degrees in Biotechnology in 2003 from the University of Nevada, Reno, and was one of three students in the inaugural advanced BS/MS Biotechnology Program. He distinguished himself as the first student to complete the program. Lancer came to Sierra Sciences as an intern while completing his degree. Following graduation, he joined Sierra Sciences full-time where he has proven to have remarkable ability to engineer genes and DNA. He has recently been promoted to Program Director of Screening.

Our Management Team

Jonathan Greenwood/Park

CEO

Business professional

Jonathan studied and finished his Architect design school at University of Auckland and the Collage of Hong-Ik from 1993 to 1998.

He was a marketing manager at Tweeddale's Honey and Brings Business consulting company from 1999 to 2003, Jonathan was one of the sales and marketing department of both companies for this work

He had introduced Manuka honey and Ugg Boots in Asian market successfully.

After he had worked at Antipodean pharmaceutical Inc as an agent, he met Dr Andrews in New Zealand.

He has started Defytime Limited as anti aging company in 2013.

Deug-yong Shin

CTO

Professor , Dankook University

Dr. Shin received his PhD in 1989 at the University of Tokyo, Japan, then moved to NIH, USA and worked as a postdoc fellow at lab of Dr. R. Crouch (NICHD) from 1989 to 1991, and as a research associate at lab of Dr. S. A. Aaronson (NCI) from 1991 to 1995. After 6 year posrdoc careers at NIH, he started to conduct his research as a principle investigator at Korea Research Institute of Bioscience and Biotechnology (KRIBB) from 1995. From March of 2000, he has been served as a professor at Dankook University College of Medicine, Korea to present.

Dr Shin provided first evidence that p53 tumor suppressor gene can induce senescence in human tumor cells, which was published on PNAS at 1997, which was his first paper as a PI. By this paper, he suggested a novel cancer therapy to induce senescence in human tumors. He also interested in senescence of articular chondrocyte. and found a novel signaling pathway of chondrocyte senescence, which is mediated by p38MAPK and regulated by immune suppressants, such as CsA and FK506. He recently focused on novel genes, which are screened by a functional cDNA expression cloning strategy, that regulate cell death and senescence. These studies give an insight to regulation of aging process and development of aging-related diseases.

Telomeres



Telomeres are an essential part of human cells that affect how our cells age

Cell division plays a critical role in normal growth, maintenance and repair of all human tissues, including skin

Telomeres are repeated sequences of DNA at the ends of each chromosome and are key genetic elements involved with the regulation of cell division. Telomeres shorten every time a cell divides, and once telomeres reach a critically short length, the cell either dies by apoptosis or stops dividing and senesces.

Telomeres are the caps at the end of each strand of DNA that protect our chromosomes, like the plastic tips at the end of shoelaces. Without the coating, shoelaces become frayed until they can no longer do their job, just as without telomeres, DNA strands become damaged and our cells can't do their job.

Telomeres are shortened as we age, but telomeres can also be shortened by stress, smoking, obesity, lack of exercise and a poor diet.




As cells divide over time telomeres shorten, and eventually cell division stops

Telomerase

Telomerase is a naturally occurring enzyme that maintains telomeres and prevents them from shortening during cell division

Telomerase, also called telomere terminal transferase, is a ribonucleoprotein that adds the polynucleotide "TTAGGG" to the 3' end of telomeres, at the ends of eukaryotic chromosomes

Telomerase is a reverse transcriptase enzyme that carries its own RNA molecule (with the pattern of "CCCAAUCCC" in vertebrates), which is used as a template for adding new bases onto the ends of telomeres




What is Aging?

Ageing (British English) or aging (American English) is just the process of becoming older

The term is used to refer to biological aging of human beings, animals and other organisms, but can also refer to individual cells within an organism (cellular aging) or to the population of a species (population aging)

In humans, aging is an accumulation of changes over time, encompassing physical, psychological, and social change. Reaction time may slow with age, while knowledge and wisdom may expand. Aging is one of the greatest contributing risk factors for most human diseases, and of the roughly 150,000 people who die each day across the globe, about two thirds die from age-related causes



Causes & Treatment of Aging

Telomerase Induction

The causes of aging can be ascribed to damage, whereby the accumulation of externally induced damage (such as DNA point mutations) may cause biological systems to fail, or to programmed aging, whereby internal processes (such as DNA telomere shortening) may cause aging.

Telomere-shortening can be seen as a programmed aging 'disease', and could be cured by lengthening telomeres via **Telomerase Induction**.

Defytime proposes different Telomerase Induction methods:

- **Anti Aging Therapeutic** used in creams, supplements, and water
- **Nano Bubble Solution** available in 2021 our clinic in New Zealand for VVIP patients

The next 2 pages explain how these processes work

The activation of telomerase in aged mice rejuvenates the entire body



With telomerase aging is reversed


Without telomerase aging continues

Anti Aging Therapeutic

Telomerase Induction Method 1

Telomerase can be naturally produced by your cells to repair telomeres, but this function is shut off by a repressor protein binding to a regulator site or 'switch' on the chromosome

- Defytime introduces a therapeutic element that binds to the repressor protein
- This prevents the repressor protein from binding to the regulator site, allowing telomerase production to be activated
- The telomerase produced by your cells can then repair the portions of the telomeres lost in cell division




Nano Bubble Solution

Telomerase Induction Method 2

In Defytime Telomere Lengthening Therapy, a nano bubble combining the Telomerase Activating Molecule.

- The telomerase produced by your cells can then repair the portions of the telomeres lost in cell division
- Transfers into deep skin cells and produce telomerase.
- Hydrate nano bubble solution delivered into the deep skins




Nano Bubbles with
Nano Bubble Generator

+

TAM Solution

=

Nano Bubble
Solution



TAM CO314818



Telomerase Activating Molecule

Developed by Bill Andrews, Ph D (Sierra Sciences, LLC)
in 2014, TAM CO314818 is a state of the art Telomerase
Activating Molecule (TAM) that counteracts and suppresses
the fundamental cause of aging: telomere shortening

By interfering with the action of telomerase inhibiting substances TAM
CO314818 induces telomerase to function normally and to cause cell d
ivision to become more active leading to younger and healthier cells

TAM is the most effective anti-aging compound available, being 300
times more effective than TA65 - currently the strongest telomerase i
nducer in the market

The TAM compound is mixed with other ingredients for oral and dermal
products All Defytime products feature the TAM logo to indicate they
contain the TAM compound



TAM Clinical Studies

Excellent improvement of skin condition over 30 days

Clinical trials in vivo in Italy (Abich Labs in cooperation with San Raffaele Hospital) proved the strong anti-aging properties of our TAM products

- 100 women tested, 36-65 years old
- Applied twice daily, 20ug/ml TAM
- Tested on day 0, 15, 30



Day 0



Day 15




Day 30

Defytime Bill Andrews Aging Care Capsules

With Telomerase Activation

- Defytime Dr Bill Andrews anti-aging dietary supplement with TAM improves biological health (skin, vessels, brain, bone)
- Made in New Zealand from quality ingredients
- TAM targets telomeres in cells, leading to younger and healthier cells
- TAM is the most effective anti-aging compound available



Defytime Aging Care Cream

With Telomerase Activation

- Defytime Aging Care Cream with TAM counteracts and suppresses the fundamental cause of skin aging: telomere shortening. Skin cells are rejuvenated, youthful elasticity is restored, fine lines and wrinkles disappear.
- A state of the art natural micro-emulsion optimized to deliver TAM to achieve maximum results.
- Made in New Zealand from quality ingredients.
- TAM targets telomeres within skin tissue, leading to younger and healthier skin cells.
- TAM is the most effective anti-aging compound available.



Defytime Eye Serum

With Telomerase Activation

- Defytime Eye Serum with Jojoba Oil and Macadamia Seed Oil Esters along with TAM acts to prevent premature aging of the skin
- Made in New Zealand from quality ingredients
- TAM targets telomeres within skin tissue, leading to younger and healthier skin cells
- TAM is the most effective anti-aging compound available



Defytime Deep Skin Express

Rejuvenating Eye Patch with Telomerase Activation

- Defytime Deep Skin Express rapidly delivers active ingredients into the deep dermal layer of the skin for lasting effects
- Convenient and fast application (1 minute)
- Over 1.5mm absorption into the dermal layer after 50 minutes
- Made in New Zealand from 100% natural and sustainable ingredients
- Dermal tested and hypoallergenic
- TAM targets telomeres within skin tissue, leading to younger and healthier skin cells, and is the most effective anti-aging compound available



Defytime Aqua Oil Drops

With Telomerase Activation

- Defytime Aqua Oil Drops with Rosehip Oil, Macadamia Oil and Astaxanthin Oil along with TAM offers a wide range of skin health benefits when used regularly
- Made in New Zealand from quality ingredients
- TAM targets telomeres within skin tissue, leading to younger and healthier skin cells
- TAM is the most effective anti-aging compound available



Defytime TAM Spray

With Telomerase Activation

- Defytime TAM Spray with Aqueous Propolis helps to improve biological health, while preventing dry mouth, tooth decay and gum disease naturally
- Made in New Zealand from natural ingredients and free of sugar and preservatives
- Promotes production of saliva as well as providing active anti-bacterial properties against tooth decay, gingivitis and bad breath
- TAM targets telomeres in cells, leading to younger and healthier cells, and is the most effective anti-aging compound available



Defytime Facial mask

With Telomerase Activation

- Defytime Deep Skin Express Rejuvenating Facial Mask with TAM targets telomeres within the deep layers of your skin for lasting rejuvenation.
- Easy and effective application.
- TAM restores telomeres within skin tissue, leading to younger and healthier skin.
- TAM is the most effective anti-aging compound available.
- Made in New Zealand from natural ingredients.



Brand Marketing Strategy



SWOT Analysis

Strength

Genuine anti aging and cure aging solution

Weakness

New mechanism

Opportunity

Unlimited market

Threat

Similar products could create confusion for consumers

SWOT

- As a new idea it may take time for consumers to understand the mechanism, but when consumers accept the idea it will create a huge market for the long term
- So, we need to spend time and money on marketing and branding Bill's name as the leading telomere expert. We also need to find the right channels to sell.

Business Time Table

	➡ March 30, 2021	➡ Dec 30, 2021	➡ Jun 30, 2022	➡ Nov 30, 2022
Business Plan	➡ March 30 2021 (restructure web sites)	➡	DR Shin & his Team will complete efficacy test	➡ Support Hong to climb up Lhotse
Market Research	➡ March 30, 2020 (market testing already completed)			
Complete Contract		➡ Completed 28th March, Reno USA		
Set Up Company	➡ Completed March 30, 2021 (Defytime USA - expecting initial fund)			
Invest Fund	➡ March 30, 2021 (invest actual fund)			
Prototype Nano Bubble Machines		➡ June 15 (1st machine with initial fund)		
Produce Samples	➡ Feb 25 - March 30, 2021 (by Defytime, NZ)			
Test Production	➡ March 2021			
Nano Bubble Sales			➡ Only for VVIP 2021 by booking / 10 clinical tests	
Mass Production & Sales		➡		

Requested Investment

Total: US\$19Million

Details	Amount (US\$)	Notes
License fee	3 Million	
NZ clinic center	5 Million	Includes property cost(\$3Million)
clinic tests	2 Million	50 persons
Nano Bubble System manufacturing factory setup costs	1 Million	
New drug development costs	2 Million	Until clinic phase 2/A
Marketing costs for dermal and oral	1 Million	Branding, PR
Manufacturing costs for cosmetics	2 Million	Mask patch, serum, cream, oral & nasal spray, capsules, oil
Operation costs	3 Million	Yearly
Subtotal	19Millions	

Cosmeceutical Estimated Sales

Defytime Aged Care Crème	2022	2023	2024	2025	2026
Unit price (USD\$)	1500	1500	1500	1500	1500
Growth rate pa %	0	5%	10%	15%	20%
Sales volume (units)	35,000	36,750	40,425	46,489	55,787
Annual Revenue	52,500,000	55,125,000	60,637,500	69,733,125	83,679,750
COGS	9,450,000	9,922,500	10,914,750	12,551,963	15,062,355
Gross margin	43,050,000	45,202,500	49,722,750	57,181,163	68,617,395
GM%	82%	82%	82%	82%	82%



High-end anti aging products in the US , Japan and China:
 Prevage retails for about \$175, and StriVectin for about \$185 Based on the current pricing of Prevage and StriVectin, the company plans to price at more than \$250 00

The **global cosmeceutical** market size was estimated at USD 52.4 billion in 2019 and is expected to reach USD 55.4 billion in 2020.

What is the **cosmeceutical** market growth? The **global cosmeceutical** market is expected to grow at a compound annual growth rate of 5.1% from 2019 to 2025 to reach USD 70.0 billion by 2025.

Cosmeceutical Estimated Sales

Defytime Eye Serum	2022	2023	2024	2025	2026
Unit price (USD\$)	250	250	250	250	250
Growth rate pa %	0	5%	10%	20%	30%
Sales volume (units)	50,000	52,500	57,750	69,300	90,090
Annual Revenue	12,500,000	13,125,000	14,437,500	17,325,000	22,522,500
COGS	2,250,000	2,362,500	2,598,750	3,118,500	4,054,050
Gross margin	10,250,000	10,762,500	11,838,750	14,206,500	18,468,450
GM%	82%	82%	82%	82%	82%



High-end anti aging products in the U S , Japan and China:
Prevage retails for about \$175, and StriVectin for about \$185 Based on the current pricing of Prevage and StriVectin, the company plans to price at more than \$250 00

The **global cosmeceutical** market size was estimated at USD 52.4 billion in 2019 and is expected to reach USD 55.4 billion in 2020.

What is the **cosmeceutical** market growth? The **global cosmeceutical** market is expected to grow at a compound annual growth rate of 5.1% from 2019 to 2025 to reach USD 70.0 billion by 2025.

Cosmeceutical Estimated Sales

Defytime Deep Skin Eye Patch	2022	2023	2024	2025	2026
Unit price (USD\$)	250	250	250	250	250
Growth rate pa %	0	15%	20%	30%	40%
Sales volume (units)	20,000	23,000	27,600	35,880	50,232
Annual Revenue	5,000,000	5,750,000	6,900,000	8,970,000	12,558,000
COGS	750,000	862,500	1,035,000	1,345,500	1,883,700
Gross margin	4,250,000	4,887,500	5,865,000	7,624,500	10,674,300
GM%	85%	85%	85%	85%	85%



High-end anti aging products in the U S , Japan and China:

Prevage retails for about \$175, and StriVectin for about \$185 Based on the current pricing of Prevage and StriVectin, the company plans to price at more than \$250 00

The **global cosmeceutical** market size was estimated at USD 52.4 billion in 2019 and is expected to reach USD 55.4 billion in 2020.

What is the **cosmeceutical** market growth? The **global cosmeceutical** market is expected to grow at a compound annual growth rate of 5.1% from 2019 to 2025 to reach USD 70.0 billion by 2025.

Cosmeceutical Estimated Sales

Defytime Aqua Oil Drops	2022	2023	2024	2025	2026
Unit price (USD\$)	300	300	300	300	300
Growth rate pa %	0	5%	10%	15%	20%
Sales volume (units)	5,000	5,250	5,775	6,641	7,970
Annual Revenue	1,500,000	1,575,000	1,732,500	1,992,375	2,390,850
COGS	270,000	283,500	311,850	358,628	430,353
Gross margin	1,230,000	1,291,500	1,420,650	1,633,748	1,960,497
GM%	82%	82%	82%	82%	82%



High-end anti aging products in the US , Japan and China:
Prevage retails for about \$175, and StriVectin for about \$185 Based on the current pricing of Prevage and StriVectin, the company plans to price at more than \$250 00

The **global cosmeceutical** market size was estimated at USD 52.4 billion in 2019 and is expected to reach USD 55.4 billion in 2020.

What is the **cosmeceutical** market growth? The **global cosmeceutical** market is expected to grow at a compound annual growth rate of 5.1% from 2019 to 2025 to reach USD 70.0 billion by 2025.

Cosmeceutical Estimated Sales

Defytime Deep Skin Facial Mask	2022	2023	2024	2025	2026
Unit price (USD\$)	300	300	300	300	300
Growth rate pa %	0	15%	20%	30%	40%
Sales volume (units)	150,000	172,500	207,000	269,100	376,740
Annual Revenue	45,000,000	51,750,000	62,100,000	80,730,000	113,022,000
COGS	6,750,000	7,762,500	9,315,000	12,109,500	16,953,300
Gross margin	38,250,000	43,987,500	52,785,000	68,620,500	96,068,700
GM%	85%	85%	85%	85%	85%



High-end anti aging products in the U S , Japan and China:
Prevage retails for about \$175, and StriVectin for about \$185 Based on the current pricing of Prevage and StriVectin, the company plans to price at more than \$250 00

The **global cosmeceutical** market size was estimated at USD 52.4 billion in 2019 and is expected to reach USD 55.4 billion in 2020.

What is the **cosmeceutical** market growth? The **global cosmeceutical** market is expected to grow at a compound annual growth rate of 5.1% from 2019 to 2025 to reach USD 70.0 billion by 2025.

Non-medicated Item Estimated Sales

Defytime TAM Spray	2022	2023	2024	2025	2026
Unit price (USD\$)	200	200	200	200	200
Growth rate pa %	0	5%	10%	15%	20%
Sales volume (units)	100,000	105,000	115,500	132,825	159,390
Annual Revenue	20,000,000	21,000,000	23,100,000	26,565,000	31,878,000
COGS	4,000,000	4,200,000	4,620,000	5,313,000	6,375,600
Gross margin	16,000,000	16,800,000	18,480,000	21,252,000	25,502,400
GM%	80%	80%	80%	80%	80%



The health and wellness food market is poised to grow by USD 1,299.84 billion during 2020-2024 progressing at a CAGR of over 6% during the forecast period.
 The "YOY (year-over-year) **growth** rate for 2021 is estimated at 6%" by the end of 2024.

Non-medicated Item Estimated Sales

Defytime Aged Care Capsule	2022	2023	2024	2025	2026
Unit price (USD\$)	800	800	800	800	800
Growth rate pa %	0	8%	15%	20%	30%
Sales volume (units)	40,000	43,000	49,450	59,340	77,142
Annual Revenue	32,000,000	34,400,000	39,560,000	47,472,000	61,713,600
COGS	5,760,000	6,192,000	7,120,800	8,544,960	11,108,448
Gross margin	26,240,000	28,208,000	32,439,200	38,927,040	50,605,152
GM%	82%	82%	82%	82%	82%




The health and wellness food market is poised to grow by USD 1,299.84 billion during 2020-2024 progressing at a CAGR of over 6% during the forecast period.
The "YOY (year-over-year) **growth** rate for 2021 is estimated at 6%" by the end of 2024.

Cash Flow Analysis Assumptions

Defytime Products Total	2022	2023	2024	2025	2026
Annual Revenue	167,000,000	181,150,000	206,735,000	250,795,125	325,373,850
COGS	28,960,000	31,302,000	35,604,300	42,983,423	55,437,453
Gross margin	138,040,000	149,848,000	171,130,700	207,811,703	269,936,397
GM%	83%	83%	83%	83%	83%

About Nano-bubble Clinic



Defytime Nanobubble Service		
1Time	USD20,000	Antiaging, moisture, healing, hair treatments
10Times	USD150,000	
100Times	USD1,000,000	
Defytime Installation Service available		

Telomere Lengthening Therapy Estimated Sales

Telomere Lengthening Therapy	2022	2023	2024	2025	2026
Unit price (USD\$)	2,000,000	2,000,000	2,000,000	2,000,000	2,000,000
Growth rate pa %	0	10%	100%	300%	750%
Sales volume (units)	10	11	22	88	748
Annual Revenue	20,000,000	22,000,000	44,000,000	176,000,000	1,496,000,000
COGS	5,000,000	5,500,000	11,000,000	44,000,000	374,000,000
Gross margin	15,000,000	16,500,000	33,000,000	132,000,000	1,122,000,000
GM%	75%	75%	75%	75%	75%

Defytime Estimated Sales

Defytime Summary	2022	2023	2024	2025	2026
Annual Total Revenue	187,000,000	203,150,000	250,735,000	426,795,125	1,821,373,850
COGS	33,960,000	36,802,000	46,604,300	86,983,423	429,437,453
Gross margin	153,040,000	166,348,000	204,130,700	339,811,703	1,391,936,397
GM%	82%	82%	81%	80%	76%
Other Expenses					
Marketing	6,000,000	6,000,000	7,500,000	14,500,000	80,000,000
Operating expenses	4,500,000	5,750,000	7,500,000	15,500,000	65,750,000
R&D related costs	1,500,000	1,500,000	1,500,000	1,500,000	1,500,000
Total Expenses	12,000,000	13,250,000	16,500,000	31,500,000	147,250,000
Operating Profit	141,040,000	153,098,000	187,630,700	308,311,703	1,244,686,397

Defytime Limited Valuation

Assumptions

Global cosmeceutical market size was estimated at US\$52.4 billion in 2019 and is projected to rise to US\$55.4 billion in 2020, with a year on year growth rate of 5.73%.

The global cosmeceutical market growth rate is projected at 5.1% annually between 2019 and 2025. By 2025 the global market size will be US\$70.0 billion.

Defytime's existing product range is priced in the medium to upper segment range. Its prices are slightly higher than the Prevage and StriVectin brands.

Defytime Limited financial year end is 31 March

All figures are in USD\$, unless otherwise stated

Revenue projections are based upon nominal market penetration, given size of cosmeceutical market and sector

Revenue projections are predicated upon marketing spend occurring and minimal R&D spend occurring.

Projections are reliant upon a number of assumptions and are therefore often different to real world results


Defytime Limited has over \$3 million of existing product inventory on hand to be able to be sold.

EBIT multiple range 10 to 15 times as high growth company with transformational technology

Defytime Limited Valuation

Defytime Summary	2022	2023	2024	2025	2026		
Annual Total Revenue	187,000,000	203,150,000	250,735,000	426,795,125	1,821,373,850		
COGS	35,530,000	38,598,500	50,147,000	93,894,927	437,129,724		
Gross margin	151,470,000	164,551,500	200,588,000	332,900,198	1,384,244,126		
GM%	81%	81%	80%	78%	76%		
Other Expenses							
Marketing	6,000,000	6,000,000	7,500,000	14,500,000	80,000,000		
Operating expenses	4,500,000	5,750,000	7,500,000	15,500,000	65,750,000		
R&D related costs	1,500,000	1,500,000	1,500,000	1,500,000	1,500,000		
Total Expenses	12,000,000	13,250,000	16,500,000	31,500,000	147,250,000		
Operating Profit	139,470,000	151,301,500	184,088,000	301,400,198	1,236,994,126		
EBIT Multiple X							
6	836,820,000	907,809,000	1,104,528,000	1,808,401,188	7,421,964,756		
10	1,394,700,000	1,513,015,000	1,840,880,000	3,014,001,980	12,369,941,260		
Valuation Summary							
Given Defytime's business model is based upon some very unique and potentially life changing technology and ingredients, plus little effective cosmaceutical market penetration is required to derive a significant revenue outcome, the company is valued, based upon the provided projections between USD\$836million and \$1,390million in 2022. The company valuation increases significantly post 2022.							

Company & Brand Structure



Proposed Summary Terms

Investment: 19 Million USD

Summary Terms Description	
Target	Investors from overseas 19 million USD The terms for the investment include receiving 30% of Defytime Limited The entire business will operate with Defytime NZ capital of 19 million USD by purchasing or investing for the corporations shown in the Company & Brand Structure diagram The business model for R&D and IPO will commence with the primary investment
Defytime HQ Shareholders	Bill Andrews 20% Jonathan Greenwood 40% Investors 30% Others 10%
Defytime Singapore	A company targeted to be listed in the stock market (the target company for value maximization) Backdoor listing by securing the capital, or direct listing after 3~5 years If backdoor listing possible share premium realization through continuous R&D If direct listing: attracts large scale funds (attracting institutional and general investment when IPO)
Sierra Sciences LLC	Know how and patient management under the supervision of Dr Bill Materials research and drug development, strategic management of intellectual property
Defytime Science	Drug Design Company Promotes new drug development based on Sierra Sciences' findings Development of new drugs and health foods
Defytime Limited	Dermal related new product development and sales company management Performs the role of a cash-cow
Alternatif NZ Ltd	Dermal Production Base
Defytime Japan Defytime Dubai Defytime USA	Regional sales or marketing subsidiary corporations Attract investors with marketing skills and financing capacity in their region (Joint Venture established) Management and control through sales licenses

Company Structure

Name of Company	Defytime Limited (HQ)
CEO	Jonathan Greenwood
Capital	\$500,000 00
Sale	\$500,000 00
Products	Defytime Facial Serum, Mask Patch, Nasal Spray
Employees	8
Place	New Zealand, Singapore, Hong Kong
Email	biotechnz@gmail com, jonathan@defytime com
Website	www defytime com

Name of Company	Share Holder	Relationship	Number of Shares
Defytime Holdings Limited	Jonathan Greenwood	CEO	70



Thank you

defytimeTM

[www defytime com](http://www.defytime.com)